US$ 21.88
glp-1 connecticut is moving to eliminate Medicaid coverage of weight loss drugs like Ozempic and Mounjaro, a decision that could leave thousands of residents without access to medications that have transformed obesity Connecticut wants to lower rising
Description
As long as the drug is not an "essential copy," or a direct copy of the original drug, they believe they have the right to sell in order to meet demand
In a phase II trialExternal link, the medication, injected once a week, met its primary endpoint of statistically significant weight loss
Retrieved from Hamrick, I., Norton, D., Birstler, J., et al

[DOI] [PMC free article] [PubMed] [Google Scholar] 202.Chen Y, Li Z, Yang Q, et al

10.1172/JCI112855 89 MooreB
